Novavax (NVAX) Misses Q1 EPS by 13c; offers outlook
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.32 +3.56%
Revenue Growth %: -78.2%
Financial Fact:
General and administrative: 13.56M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -78.2%
Financial Fact:
General and administrative: 13.56M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q1 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $93.85 million versus the consensus estimate of $141.16 million.
GUIDANCE:
Novavax sees FY2024 revenue of $800 million to $1 billion, versus the consensus of $845.5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
